Li Xin, Yuan Li, Li Jin, Li Hailing, Cheng Suosuo
Department of Endocrinology, Zhongnan Hospital, Wuhan University, 169 Donghu Road, Wuhan 430071, China.
Exp Diabetes Res. 2012;2012:618923. doi: 10.1155/2012/618923. Epub 2012 Nov 12.
This study aimed to investigate whether rennin-angiotensin system (RAS) blockade through telmisartan would increase the resistance to streptozotocin- (STZ-) induced diabetes in insulin resistance rats. There were sixty Wistar rats that were divided into four groups: normal control (NC), high-fat diet (HF), high-fat diet plus STZ injection (HF+S), and high-fat diet plus STZ injection and telmisartan intervention (HF+S+T). Five rats were chosen randomly and respectively from groups NC and HF to undergo a hyperinsulinemic euglycemic clamp. Another five rats were selected randomly from the four groups, respectively, for intravenous injection insulin releasing test (IVIRT), and the other five rats for pancreas specimens used in islet cell immunohistochemistry staining (stained for insulin, NF-κB, and caspase-3), islet cell apoptosis staining, and reverse transcription PCR (AT1R and IL-1 beta). There was a significant difference of overt diabetes incidence between groups HF+S+T and HF+S (P < 0.05). Furthermore, inflammatory markers and islet cell apoptosis were found to be significantly reduced in group HF+S+T compared with group HF+S (all P < 0.01 or P < 0.05). Overall, telmisartan-treated rats were found to have reduced RAS activity, increased resistance to STZ-induced diabetes, reduced inflammatory markers, and improvement of islet cell function and morphology.
本研究旨在探讨通过替米沙坦阻断肾素 - 血管紧张素系统(RAS)是否会增加胰岛素抵抗大鼠对链脲佐菌素(STZ)诱导的糖尿病的抵抗力。将60只Wistar大鼠分为四组:正常对照组(NC)、高脂饮食组(HF)、高脂饮食加STZ注射组(HF + S)和高脂饮食加STZ注射及替米沙坦干预组(HF + S + T)。从NC组和HF组中分别随机选取5只大鼠进行高胰岛素 - 正血糖钳夹试验。从四组中分别再随机选取5只大鼠进行静脉注射胰岛素释放试验(IVIRT),另外5只大鼠用于胰腺标本的胰岛细胞免疫组织化学染色(检测胰岛素、NF - κB和caspase - 3)、胰岛细胞凋亡染色以及逆转录聚合酶链反应(检测AT1R和IL - 1β)。HF + S + T组和HF + S组之间的显性糖尿病发病率存在显著差异(P < 0.05)。此外,与HF + S组相比,HF + S + T组的炎症标志物和胰岛细胞凋亡显著降低(均P < 0.01或P < 0.05)。总体而言,发现替米沙坦治疗的大鼠RAS活性降低,对STZ诱导的糖尿病的抵抗力增加,炎症标志物减少,胰岛细胞功能和形态得到改善。